The European Medicines Agency (EMA) has halted Eisai and Biogen鈥檚 expansion plan to launch its Alzheimer鈥檚 disease therapy Leqembi (lecanemab) in Europe after its drug review committee recommended against the therapy鈥檚 approval.
The Committee for Medicinal Products for Human Use (CHMP) stated that Leqembi鈥檚 positive effect on delaying cognitive decline was 鈥渘ot large enough鈥� to counterbalance the associated risk of serious adverse events. Eisai was quick to add that the company plans to re-examine the CHMP opinion.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The committee was particularly concerned with the risk of developing amyloid-related imaging abnormalities (ARIA). These are observed exclusively on MRI and can signify oedema, effusion and /or haemorrhage.
CHMP noted that 鈥渁lthough most cases of ARIA in the main study were not serious and did not involve symptoms, some patients had serious events, including large bleeds in the brain which required hospitalisation.鈥� The risk of ARIA was increased in patients with ApoE4 gene, the presence of one or more copies of the gene predisposes an individual to develop Alzheimer’s disease.
The committee also pointed out that the difference in the , measured using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score, between the Leqembi and placebo arms was 鈥渟mall鈥�. Adding that 鈥渢he seriousness of this side effect should be considered in the context of the small effect seen with [Leqembi].鈥�
Leqembi works by targeting the buildup of amyloid plaques in the brain, a hallmark of Alzheimer鈥檚 disease and a suggested cause of memory and cognition impairment. It received accelerated approval from the US Food and Drug Administration (FDA) in January, which was converted into full approval earlier this month.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLeqembi is an important 聽drug for Biogen, which is codeveloping the drug with Eisai, especially after the former discontinued its other controversial Alzheimer鈥檚 treatment Aduhelm (aducanumab-avwa), in January. A GlobalData analysis forecasts Leqembi to generate over $6.1bn in sales by 2030.
GlobalData is the parent company of 色界吧 Technology.
Eisai and Biogen have also filled a supplemental biologics application (sBLA) with the US FDA for monthly Leqembi IV maintenance dosing for the treatment of patients with Alzheimer鈥檚 disease, with the Prescription Drug User Fee Act (PDUFA) action date being set for 25 January 2025.
